Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | TSHR | P16473 | 5/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771134 | 0.89 | ALDH1A1 (0.72) | ALDH1A1TSHRTDP1GPR35CYP3A4 | |
| SCHEMBL30435223 | 0.87 | ALDH1A1 (0.61) | ALDH1A1TSHRTDP1GPR35CYP3A4 | |
| SCHEMBL9452637 | 0.87 | ALDH1A1 (0.61) | ALDH1A1TSHRTDP1GPR35CYP3A4 | |
| SCHEMBL26694938 | 0.86 | ALDH1A1 (0.50) | ALDH1A1TSHRTDP1GPR35CYP3A4 | |
| SCHEMBL27725655 | 0.86 | ALDH1A1 (0.55) | ALDH1A1TSHRTDP1GPR35CYP3A4 | |
| SCHEMBL28291579 | 0.86 | ALDH1A1 (0.50) | ALDH1A1TSHRTDP1GPR35CYP3A4 | |
| SCHEMBL8791047 | 0.81 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1GPR35CYP3A4 | |
| SCHEMBL28180984 | 0.81 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1GPR35CYP3A4 | |
| SCHEMBL9944130 | 0.81 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1GPR35CYP3A4 | |
| SCHEMBL6436847 | 0.81 | VCAM1 (0.56) | ALDH1A1TSHRTDP1GPR35CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0687263-B1 | PROCESS FOR PREPARING (TRANS)-6- [2-(SUBSTITUTED-PYRROL-1-YL)ALKYL]PYRAN-2-ONE INHIBITORS OF CHOLESTEROL SYNTHESIS | WARNER LAMBERT CO (US) | 1997-07-30 | — | — | EP | claimed |
| EP-0330172-B1 | Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER LAMBERT CO (US) | 1994-08-10 | — | — | EP | claimed |
| CN-120682158-A | Nitrogen-containing heterocyclic compound, and preparation method and application thereof | 山东阳谷华泰化工股份有限公司 | 2025-09-23 | — | — | CN | disclosed |
| US-10869934-B2 | Antiproliferative compounds and conjugates made therefrom | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-22 | — | — | US | disclosed |
| US-10398783-B2 | Antiproliferative compounds and conjugates made therefrom | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| WO-2018075842-A1 | CONDENSED BENZODIAZEPINE DERIVATIVES AND CONJUGATES MADE THEREFROM | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-26 | — | — | WO | disclosed |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | BRISTOL-MYERS SQUIBB COMPANY | 2018-04-26 | — | — | US | disclosed |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | BRISTOL-MYERS SQUIBB COMPANY | 2018-04-26 | — | — | US | disclosed |
| EP-2066673-B1 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | CHEMBRIDGE CORP (US) | 2016-12-28 | — | — | EP | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-4426385-A | Insecticidal bicyclooxyphenyl ureas | UNION CARBIDE CORPORATION (US) | 1984-01-17 | — | — | US | disclosed |
| EP-0050321-A2 | Novel bicyclooxyphenyl ureas, process for their preparation and pesticides containing them | UNION CARBIDE CORPORATION (US) | 1982-04-28 | — | — | EP | disclosed |
| US-4287372-A | Preparation of nitro-substituted diphenyl ethers | UOP INC. (US) | 1981-09-01 | — | — | US | disclosed |
| US-4228103-A | Effecting condensation of nitrohaloarene and formyl derivative of a primary aromatic amine with alkali metal hydroxide | MONSANTO COMPANY (US) | 1980-10-14 | — | — | US | disclosed |
| US-4209463-A | Promoting the formation of nitrodiarylamines from nitrohaloarenes, activated aryl amines and sodium carbonates | MONSANTO COMPANY (US) | 1980-06-24 | — | — | US | disclosed |
| US-4196146-A | Making nitrodiarylamines from formyl derivatives of aromatic amines and nitrohaloarenes by admixing with certain aqueous salt solutions | MONSANTO COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4187248-A | FORMANILIDE | MONSANTO COMPANY (US) | 1980-02-05 | — | — | US | disclosed |
| US-4187249-A | COMPOUNDS OF POTASSIUM, CESIUM, OR RUBIDIUM | MONSANTO COMPANY (US) | 1980-02-05 | — | — | US | disclosed |
| US-4140716-A | Process for making an amide of formic acid and forming nitrodiarylamine therefrom | MONSANTO COMPANY (US) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | MKI67, HDGF, PCLAF | ALDH1A1 314/4885TSHR 1412/4885TDP1 2711/4885 |
| US-10869934-B2 | Antiproliferative compounds and conjugates made therefrom | MKI67, HDGF, PCLAF | ALDH1A1 314/4885TSHR 1412/4885TDP1 2711/4885 |
| US-10398783-B2 | Antiproliferative compounds and conjugates made therefrom | MKI67, HDGF, PCLAF | ALDH1A1 314/4885TSHR 1412/4885TDP1 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.